← All trials
NCT05727397
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 14, 2023
- Primary completion
- Nov 29, 2025
- Completion date
- Dec 29, 2025
- First posted
- Feb 14, 2023
- Last posted
- Aug 31, 2023
- Enrollment
- 432
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- RemeGenLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.